State Street SPDR S&P Pharmaceuticals ETF(XPH · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$60.36
- 52-Week Range
- $40.26 – $60.80
- YTD
- +9.33%
- IV Rank (30D)
- 24.81
- Straddle Price
- $3.75
- P/C Vol Ratio
- 5.89
Info
State Street SPDR S&P Pharmaceuticals ETF (XPH) ETF
- Exchange
- ARCX
- Inception
- 2006-06-19
- Has Options
- Yes
ETF Profile
holdings as of 2026-06-11
Holdings
59
AUM
—
Provider
SPDR (State Street)
Inception
2006-06-19
Exchange
ARCX
Data As Of
2026-06-11
Expense Ratio
0.35%
Dividend Yield
0.62%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-23 | 2026-03-25 | $0.0610 | CD |
| 2025-12-22 | 2025-12-24 | $0.1130 | CD |
| 2025-09-22 | 2025-09-24 | $0.1026 | CD |
| 2025-06-23 | 2025-06-25 | $0.0959 | CD |
| 2025-03-24 | 2025-03-26 | $0.1533 | CD |
| 2024-12-23 | 2024-12-26 | $0.1548 | CD |
Asset Allocation
Top Holdings
top 50 of 59 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | 4.36% | Equity (US) | — |
| OGN | ORGANON + CO | 3.71% | Equity (US) | — |
| LQDA | LIQUIDIA CORP | 3.28% | Equity (US) | — |
| AXSM | AXSOME THERAPEUTICS INC | 2.81% | Equity (US) | — |
| ELVN | ENLIVEN THERAPEUTICS INC | 2.32% | Equity (US) | — |
| DFTX | DEFINIUM THERAPEUTICS INC | 2.28% | Equity (US) | — |
| AMRX | AMNEAL PHARMACEUTICALS INC | 2.27% | Equity (US) | — |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 2.25% | Equity (US) | — |
| MBX | MBX BIOSCIENCES INC | 2.24% | Equity (US) | — |
| HRMY | HARMONY BIOSCIENCES HOLDINGS | 2.16% | Equity (US) | — |
| RPRX | ROYALTY PHARMA PLC CL A | 2.09% | Equity (US) | — |
| ESPR | ESPERION THERAPEUTICS INC | 2.07% | Equity (US) | — |
| VTRS | VIATRIS INC | 2.06% | Equity (US) | — |
| INDV | INDIVIOR PHARMACEUTICALS INC | 2.05% | Equity (US) | — |
| LLY | ELI LILLY + CO | 2.05% | Equity (US) | — |
| LGND | LIGAND PHARMACEUTICALS | 2.03% | Equity (US) | — |
| XERS | XERIS BIOPHARMA HOLDINGS INC | 2.02% | Equity (US) | — |
| TRVI | TREVI THERAPEUTICS INC | 1.99% | Equity (US) | — |
| PRGO | PERRIGO CO PLC | 1.96% | Equity (US) | — |
| EWTX | EDGEWISE THERAPEUTICS INC | 1.93% | Equity (US) | — |
| ANIP | ANI PHARMACEUTICALS INC | 1.89% | Equity (US) | — |
| MRK | MERCK + CO. INC. | 1.83% | Equity (US) | — |
| NUVB | NUVATION BIO INC | 1.83% | Equity (US) | — |
| ELAN | ELANCO ANIMAL HEALTH INC | 1.81% | Equity (US) | — |
| PCRX | PACIRA BIOSCIENCES INC | 1.81% | Equity (US) | — |
| HROW | HARROW INC | 1.80% | Equity (US) | — |
| INVA | INNOVIVA INC | 1.77% | Equity (US) | — |
| JNJ | JOHNSON + JOHNSON | 1.73% | Equity (US) | — |
| COLL | COLLEGIUM PHARMACEUTICAL INC | 1.70% | Equity (US) | — |
| PFE | PFIZER INC | 1.69% | Equity (US) | — |
| BMY | BRISTOL MYERS SQUIBB CO | 1.67% | Equity (US) | — |
| AMLX | AMYLYX PHARMACEUTICALS INC | 1.64% | Equity (US) | — |
| OCUL | OCULAR THERAPEUTIX INC | 1.62% | Equity (US) | — |
| CRNX | CRINETICS PHARMACEUTICALS IN | 1.60% | Equity (US) | — |
| TARS | TARSUS PHARMACEUTICALS INC | 1.58% | Equity (US) | — |
| SUPN | SUPERNUS PHARMACEUTICALS INC | 1.51% | Equity (US) | — |
| OMER | OMEROS CORP | 1.51% | Equity (US) | — |
| CRMD | CORMEDIX INC | 1.49% | Equity (US) | — |
| EYPT | EYEPOINT INC | 1.48% | Equity (US) | — |
| NKTR | NEKTAR THERAPEUTICS | 1.43% | Equity (US) | — |
| RAPP | RAPPORT THERAPEUTICS INC | 1.42% | Equity (US) | — |
| ALMS | ALUMIS INC | 1.40% | Equity (US) | — |
| AMPH | AMPHASTAR PHARMACEUTICALS IN | 1.40% | Equity (US) | — |
| TBPH | THERAVANCE BIOPHARMA INC | 1.33% | Equity (US) | — |
| SEPN | SEPTERNA INC | 1.31% | Equity (US) | — |
| PBH | PRESTIGE CONSUMER HEALTHCARE | 1.30% | Equity (US) | — |
| ZVRA | ZEVRA THERAPEUTICS INC | 1.26% | Equity (US) | — |
| PHAT | PHATHOM PHARMACEUTICALS INC | 1.23% | Equity (US) | — |
| ZTS | ZOETIS INC | 1.20% | Equity (US) | — |
| BIOA | BIOAGE LABS INC | 1.04% | Equity (US) | — |
Geographic Breakdown
Fund Holdings
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF ·
NPORT-P period 2026-06-30
(filed 2026-02-26)
Net assets:
$230M
· 61 total positions
· equity 99.97%
· non-equity 6.70%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Axsome Therapeutics Inc | Axsome Therapeutics Inc | 2.28% | $5.2M |
| 2 | Nuvation Bio Inc | Nuvation Bio Inc | 2.13% | $4.9M |
| 3 | Xeris Biopharma Holdings Inc | Xeris Biopharma Holdings Inc | 2.11% | $4.8M |
| 4 | MBX Biosciences Inc | MBX Biosciences Inc | 2.04% | $4.7M |
| 5 | EyePoint Inc | EyePoint Inc | 2.04% | $4.7M |
| 6 | Eli Lilly & Co | Eli Lilly & Co | 2.01% | $4.6M |
| 7 | Mind Medicine MindMed Inc | Mind Medicine MindMed Inc | 2.01% | $4.6M |
| 8 | Merck & Co Inc | Merck & Co Inc | 2.01% | $4.6M |
| 9 | Supernus Pharmaceuticals Inc | Supernus Pharmaceuticals Inc | 2.01% | $4.6M |
| 10 | Viatris Inc | Viatris Inc | 2.00% | $4.6M |
| 11 | Zoetis Inc | Zoetis Inc | 1.99% | $4.6M |
| 12 | Elanco Animal Health Inc | Elanco Animal Health Inc | 1.98% | $4.6M |
| 13 | Liquidia Corp | Liquidia Corp | 1.97% | $4.5M |
| 14 | Bristol-Myers Squibb Co | Bristol-Myers Squibb Co | 1.96% | $4.5M |
| 15 | Edgewise Therapeutics Inc | Edgewise Therapeutics Inc | 1.95% | $4.5M |
| 16 | Amneal Pharmaceuticals Inc | Amneal Pharmaceuticals Inc | 1.92% | $4.4M |
| 17 | Jazz Pharmaceuticals PLC | Jazz Pharmaceuticals PLC | 1.92% | $4.4M |
| 18 | Perrigo Co PLC | Perrigo Co PLC | 1.92% | $4.4M |
| 19 | Pacira BioSciences Inc | Pacira BioSciences Inc | 1.91% | $4.4M |
| 20 | Ligand Pharmaceuticals Inc | Ligand Pharmaceuticals Inc | 1.91% | $4.4M |
| 21 | Rapport Therapeutics Inc | Rapport Therapeutics Inc | 1.89% | $4.3M |
| 22 | Indivior PLC | Indivior PLC | 1.89% | $4.3M |
| 23 | Royalty Pharma PLC | Royalty Pharma PLC | 1.88% | $4.3M |
| 24 | Tarsus Pharmaceuticals Inc | Tarsus Pharmaceuticals Inc | 1.88% | $4.3M |
| 25 | Prestige Consumer Healthcare Inc | Prestige Consumer Healthcare Inc | 1.87% | $4.3M |
Showing top 25 of 59 equity holdings.
Non-equity holdings
— 2 positions,
6.70% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 6.70% | $15.4M | 2 |
Daily issuer data also available
(2026-06-13)
via ETF Constituents
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.41% | 20 |
| Feb | +0.31% | 20 |
| Mar | -1.03% | 20 |
| Apr | +1.01% | 20 |
| May | +0.84% | 20 |
| Jun | +1.26% | 21 |
| Jul | +1.59% | 20 |
| Aug | +0.85% | 20 |
| Sep | -1.44% | 20 |
| Oct | -0.56% | 20 |
| Nov | +2.87% | 20 |
| Dec | +0.54% | 20 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $57.63
SMA 50: $57.65
SMA 200: $53.91
Current: $60.27
EMA 12: $58.31
EMA 26: $57.93
MACD: 0.3747 | Signal: 0.2643
BULLISH
ADX (14): 14.64
RANGE
+DI: 38.63
−DI: 19.54
Momentum Oscillators
RSI (14): 62.41
NEUTRAL
Stoch %K: 85.50
Stoch %D: 78.17
Williams %R: -9.98
Volume & Volatility
BB Upper: $60.01
BB Lower: $55.25
OVERBOUGHT
OBV: 234,120
Vol SMA 20: 59,608
Vol ROC: 8.50%
ATR: $1.18
True Range: $1.03
HV 20: 27.5%
HV 30: 24.9%
HV 60: 25.6%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:25.773000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 24.81
- IV Rank (7D)
- 100
- Avg IV
- 31.5%
- Straddle (30D)
- $3.75
- Straddle (7D)
- $1.80
- P/C Volume
- 5.89
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.92
- Correlation (SPY)
- 51.8%
- R²
- 0.27
- Ann. Volatility
- 21.9%
- SPY Volatility
- 12.3%
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|